Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difelikefalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 20/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difelikefalin SCHEMBL20669281 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807843 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL10316464 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807733 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL19040667 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL25386632 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807720 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807719 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL21286619 | 0.98 | OPRK1 (0.98) | OPRK1OPRM1 | |
| SCHEMBL23841287 | 0.98 | OPRK1 (0.98) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024232403-A1 | COMPOSITION FOR IMPROVING COGNITIVE FUNCTION, METHOD FOR RESEARCH OF SAME, AND RESEARCH SYSTEM | ティア・リサーチ・コンサルティング合同会社 | 2024-11-14 | — | — | WO | disclosed |
| CN-112739366-B | Oral formulations of kappa opioid receptor agonists | 卡拉治疗学股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-11986509-B2 | Oligosaccharide formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230381265-A1 | OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230285497-A1 | ATOPIC DERMATITIS THERAPY WITH KAPPA OPIOID RECEPTOR AGONIST AS ADJUNCT TO TOPICAL CORTICOSTEROID | CARA THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115335072-A | Oligosaccharide formulations of kappa opioid receptor agonists | 卡拉治疗学股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381265-A1 | OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885OPRM1 5/4885 |
| US-11986509-B2 | Oligosaccharide formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.